Shane Shuttlesworth was named president in October 2007. Prior to this position, Shane was the director of marketing & operations. Prior to assuming that position, he served several management positions in regulatory affairs, quality assurance and production. His current responsibilities include overseeing operations, marketing/sales, international business development, quality assurance and regulatory affairs. He originally joined Osteogenics Biomedical in 2001 as production manager.
A native of Lubbock, TX, Shane graduated summa cum laude with a bachelor of science degree in biology from Lubbock Christian University in 2001, received an MBA in general business and an advanced certificate in health organization management from Texas Tech University in 2003, and received a masters of science in regulatory affairs and services from St. Cloud State University in 2015.
Shane currently serves on Lubbock Christian University’s Young Alumni Advisory Board. Outside interests include basketball, football, fly fishing, and spending time with his daughter.
Brandon Bartee joined Osteogenics in May 2015 as Director of Corporate Policy and General Counsel. In this role, Brandon oversees legal affairs, risk management, finance, and human resources.
Brandon was born and raised in Lubbock, Texas. He graduated from Abilene Christian University in 2006 with a bachelor of arts in financial management. He received his juris doctor from Southern Methodist University Dedman School of Law in 2010. He studied venture capital, private equity, and entrepreneurial transactions at Duke University School of Law where he received his masters of law in 2011.
Prior to joining Osteogenics, Brandon practiced law in Dallas, Texas where he represented clients in a variety of transactions related to corporate finance, M&A, capital markets, and commercial real estate.
Brandon enjoys spending time with his wife and two children, traveling, going to rock concerts, and playing golf.
Aaron Coy was named director of manufacturing in October 2020. Prior to this position, Aaron was the associate director of manufacturing quality. Prior to assuming that position, he served in management positions including production manager and senior production manager. His current responsibilities include overseeing all operations related to manufacturing and packaging, as well as manufacturing transfer from R&D, and he also supports the quality and R&D departments as needed. Aaron originally joined Osteogenics Biomedical in 2003 as a production associate.
A native of Lubbock, TX, Aaron received his bachelor’s degree in human development and family studies from Texas Tech University in 2006, and in 2016, he received his master’s degree in medical technology quality from St. Cloud State University. Aaron also holds ASQ’s Certified Biomedical Auditor and Six Sigma Green Belt certifications.
Aaron enjoys spending time with his family, and most notably, his daughter. He also enjoys watching and attending as many sporting events as possible and taking road trips with his daughter.
Courtney Riggan was named director of engineering in July 2016 after serving as senior engineering manager for two and a half years and quality engineer for three years prior to that. Her current responsibilities include overseeing design & development, risk management, complaint management, and some regulatory submissions.
Born and raised in Lubbock, TX, Courtney graduated from Texas A&M University in 2008 with a bachelor of science degree in biomedical engineering and received an M.S. in mechanical engineering from Texas Tech University in 2010.
Courtney enjoys traveling, playing Frisbee golf, and spending time with her husband and two children.
Russ Rowan was named director of marketing in July 2012 after serving as a senior marketing manager for three years. His current responsibilities include overseeing domestic and foreign marketing activities as well as supporting Osteogenics’ growing distribution network.
Born in Lubbock, TX, Russ graduated from Texas Tech University in 2002 with a bachelor of science degree in business administration and received an MBA in general business from Texas Tech University in 2015.
Prior to joining Osteogenics Biomedical in February 2009, Russ worked in the insurance industry for seven years. During this time, he held several different marketing and sales management positions of increasing responsibility.
Russ enjoys spending his spare time with his family. He also enjoys playing golf.
Headquartered in Lubbock, Texas, Osteogenics Biomedical is a leader in the development of innovative dental bone grafting products serving periodontists, oral & maxillofacial surgeons, and clinicians involved in regenerative and implant dentistry throughout the world. Osteogenics offers a complete line of bone grafting products including: enCore® combination and mineralized allografts, Zcore™ porcine xenograft, Cytoplast™ PTFE membranes, Cytoplast™ RTM collagen membranes, Vitala™ porcine pericardium collagen membranes, Zmatrix™ porcine peritoneum collagen membranes, Cytoplast™ PTFE suture, NovaBone® synthetic putty, the Pro-fix™ Precision Fixation System, and Resorba® dental sutures.
We pride ourselves in having the best customer service in the industry. Whether it’s placing an order or inquiring about a technical issue, you will always be greeted by a friendly voice who will work to quickly address your needs. Please note that online orders are for U.S. and Canadian customers only. For international orders, please contact us directly or visit our Global Network page to find a distributor.
1996
1998
1999
1999
1999
2000
2002
2003
2005
2007
2007
2008
2009
2009
2010
2010
2010
2012
2014
2015
2015
2016
2016
2016
1996
Osteogenics Biomedical enters the dental bone grafting market with a dense PTFE membrane. The company is incorporated with a mission of developing dental bone grafting products to increase the predictability of regenerative procedures.
1998
Osteogenics introduces a new patented surface technology - the Regentex™ textured surface - to the dense PTFE membrane. This 3rd generation PTFE membrane combines the benefits of a membrane occlusive to bacteria with a textured surface that helps stabilize the membrane and soft tissue flap.
1999
Osteogenics introduces the first nitride-coated ridge augmentation mesh - Osteo-Mesh™ TM-300.
1999
Osteogenics acquires Permaridge® synthetic ridge augmentation matrix from CeraMed Dental. Permaridge® helps correct alveolar ridge resorption, providing denture wearers with more stable and comfortable dentures.
1999
Osteogenics relocates to a larger manufacturing facility in Lubbock, TX.
2000
Osteogenics receives a technique patent for treating alveolar bone defects using dense PTFE membranes - the Cytoplast Technique™. The Cytoplast Technique™ for socket grafting is the first technique utilizing membranes left exposed, thereby reducing surgical time, preserving soft tissue architecture and increasing keratinzed mucosa. Because the Cytoplast™ dense PTFE membranes are impervious to bacteria, they are especially well-suited to be left exposed in the oral environment.
2002
Osteogenics expands its regenerative portfolio with the addition of Cytoplast™ PTFE Suture and Cytoplast™ RTM collagen membranes. The company is one of only two companies in the world to manufacture PTFE suture.
2003
Osteogenics receives ISO 9001 and ISO 13485 quality certifications, demonstrating compliance with strict European quality guidelines.
2005
Osteogenics moves its corporate headquarters and manufacturing operations into a new 7,000 square-foot state-of-the-art facility in Lubbock, TX.
2007
The company receives MDD/93/42/EEC certification, allowing the company to expand into Europe by distributing under the CE mark.
2007
The company applies its Regentex™ surfaced technology to its line of titanium-reinforced membranes. Osteogenics also introduces four new titanium-reinforced application-specific membrane sizes.
2008
Osteogenics Clinical Education™, a division of Osteogenics Biomedical, is established with a mission of providing interactive, hands-on clinical education in bone grafting and implant dentistry.
2009
Osteogenics introduces two application-specific titanium-reinforced membrane sizes. The new sizes are the first to incorporate pilot holes and a broader titanium frame.
2009
170 clinicians from six countries and three continents attend Osteogenics Clinical Education's™ first global bone grafting symposium in Scottsdale, Arizona.
2010
Osteogenics signs an agreement with META Advanced Medical Technology in Italy, giving the company distribution rights in the U.S. and Canada for its dental bone grafting products, including its autogenous bone collectors Micross and Safescraper®, and crestal sinus lift kit, SinCrest.
2010
Osteogenics introduces the Pro-fix™ Precision Fixation System. Pro-fix™ is first introduced with self-drilling membrane fixation screws and will soon include self-drilling tenting screws and self-tapping bone fixation screws.
2010
Osteogenics introduces enCore® Combination Allograft and enCore® Mineralized Allograft, the first dental bone grafting product introduced by Osteogenics. The combination allograft is the first particulate dental bone grafting product to combine mineralized and demineralized bone in a single bottle.
2012
Osteogenics moves into a new 10,000 square-foot manufacturing facility, adding to its corporate headquarters campus in Lubbock, Texas.
2014
Osteogenics undergoes major renovations to its corporate headquarters to maximize space for company growth.
2015
Osteogenics acquires exclusive distribution rights to sell the synthetic, osteostimulative NovaBone® Dental products in the U.S. and Canada. Within the NovaBone® product line is an especially unique product, NovaBone® Dental Putty, a pre-mixed moldable putty that is available in a variety of delivery systems.
2015
Osteogenics introduces Zcore™ porcine xenograft particulate, an osteoconductive anorganic bone mineral derived from porcine cancellous bone. Hyper-porosity of the porcine cancellous matrix and intra-particle space reduces bulk density of the graft, allowing 88 – 95% empty space for bone growth.
2016
Osteogenics acquires the exclusive North American distribution rights for the premium German dental suture brand, Resorba®. Resorba® sutures are made from unique materials that are designed especially for dentistry and are available with black 300-series stainless steel needles that enhance visualization in the mouth.
2016
Osteogenics introduces the newest product to complement the family of enCore® allografts - enCore® OD allograft, comprised of 30% mineralized cortical bone and 70% mineralized cancellous bone. enCore® OD is designed to be used with osseodensification (OD) protocols.
2016
Osteogenics expands its regenerative portfolio with the addition of absorbable collagen wound dressings - Cytoplast™ RTMPlug, RTMFoam, and RTMTape.
We are looking for the best and brightest minds to join our team. Browse our list of current job and internship opportunities, and electronically submit your resume using the form provided.
Find a Distributor
